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THREE YEARS FOLLOW-UP: ASSOCIATION OF CLINICAL AND PCR DATA WITH ACTIVE INFECTION
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SUMMARY
Twenty-four whole blood and serum samples were drawn from an eight year-old heart transplant child during a 36 months
follow-up. EBV serology was positive for VCA-IgM and IgG, and negative for EBNA-IgG at the age of five years old when the
child presented with signs and symptoms suggestive of acute infectious mononucleosis. After 14 months, serological parameters
were: positive VCA-IgG, EBNA-IgG and negative VCA-IgM. This serological pattern has been maintained since then even during
episodes suggestive of EBV reactivation. PCR amplified a specific DNA fragment from the EBV gp220 (detection limit of 100
viral copies). All twenty-four whole blood samples yielded positive results by PCR, while 12 out of 24 serum samples were
positive. We aimed at analyzing whether detection of EBV-DNA in serum samples by PCR was associated with overt disease as
stated by the need of antiviral treatment and hospitalization. Statistical analysis showed agreement between the two parameters
evidenced by the Kappa test (value 0.750; p < 0.001). We concluded that detection of EBV-DNA in serum samples of
immunosuppressed patients might be used as a laboratory marker of active EBV disease when a Real-Time PCR or another
quantitative method is not available.
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INTRODUCTION
Epstein-Barr virus (EBV) is the etiological agent of infectious
mononucleosis. Diagnosis of infectious mononucleosis is based on
characteristic clinical features and either a positive heterophil antibody
test or serology, both of which can be unreliable in young children3.
Serological markers are based on detection of viral capsid (VCA), as well
as early (EA) and nuclear antigens (NA). The presence of immunoglobulin
M antibody raised to the capsid antigen in the absence of antibody to the
nuclear antigen (EBNA) is suggestive of acute primary EBV infection
because EBNA antibodies develop in late convalescence13. However, false-
negative results may occur as a consequence of the transient nature of the
VCA-IgM response. Conversely, false-positive IgM reactions can occur
due to the presence of auto-antibodies, or cross-reactions with other
members of herpes virus family14. Differentiation of recent and past EBV
infections is particularly difficult in young children and
immunocompromised hosts due to a delayed production of EBNA
antibodies8 . In these patients, EBV plays a significant role as a cofactor in
the process of lymphoproliferative disorders such as Burkitt’s disease,
some T and B-cell lymphomas and nasopharyngeal carcinomas5,17,20.
Immunosuppressive drugs such as Cyclosporine A and tacrolimus seem
to act synergistically with EBV as tumor inducing factors6 .
EBV reactivations have been diagnosed by serologic profiles that
suggest virus replication. Serological responses, however, are delayed and
do not necessarily indicate ongoing replicative activity. Besides, they are
known to underestimate the frequency of asymptomatic EBV reactivations15
which can be of clinical importance in immunocompromised patients.
The Polymerase Chain Reaction (PCR) has been used to detect
EBV-DNA in serum samples of patients with primary and persistent
EBV infection4,9. Quantitative amplification techniques have proved
to be more reliable in clinical practice than qualitative ones to monitor
and identify immunocompromised patients at risk to develop EBV-
related lymphoproliferative disease, for instance in transplant recipient
subjects2. The most recent quantitative amplification method, Real-
Time PCR, constitutes the most suitable technique to evaluate EBV
viral load with a maximum sensitivity and specificity. However, it is
expensive, complex, and available in only a few centers18,22,23. To
circumvent this problem, a conventional EBV-DNA PCR in serum
samples with a detection limit of 100 viral copies per µg of genomic
DNA21 might be useful to monitor EBV chronically infected
immunocompromised patients at risk to develop recrudescent or severe
disseminated disease because, in these patients, serological parameters
are frequently incapable of predicting EBV reactivations.
PATIENT AND METHODS
PATIENT: We report the case of an eight-year-old boy submitted
to a heart transplant surgery at the age of six months and since then,
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following immunosuppressive therapy with cyclosporine A, recently
substituted for tacrolimus. At the age of five years, the patient presented
with signs, symptoms, and laboratory data compatible with acute
infectious mononucleosis. We have studied 24 clinical episodes
corresponding either to periods in which the child presented with signs
and symptoms suggestive of EBV reactivations or asymptomatic ones
(ambulatory care). After the first episode of EBV disease at the age of
five, the child has been sampled other 23 times in order to determine
the presence of EBV-DNA in whole blood and serum samples and
their association with clinical EBV reactivation. The boy has evolved
with progressive deterioration of clinical conditions presenting with
EBV relapses or reactivations. The boy was critically ill by the 25th
month of follow-up (late-onset of chronic transplant rejection and
disseminated EBV disease), with an unexpected recovering after the
30th month, being clinically stable since then.
SEROLOGY: IgG antibodies to VCA were determined by capture
ELISA (Diasorin, Italy); VCA- IgG positive > 20 AU/mL and VCA-IgM
positive (qualitative test). IgG to EBNA (nuclear antigen) was determined
by ELISA (Sanofi Diagnostics Pasteur, France). The samples were
classified as: acute EBV infection (positive for IgM and IgG to VCA but
negative to IgG-EBNA; post-acute EBV infection or EBV carrier state
(positive for IgG to VCA and IgG-EBNA but negative for IgM to VCA);
EBV-seronegative individual (negative for the three serological markers).
Tests were performed according to the instructions of manufacturers
and also following the protocols described elsewhere1,9,10.
DNA EXTRACTION FROM WHOLE BLOOD: Peripheral
blood leukocytes and serum samples were drawn twenty-four times
during 24 clinical events, after informed consent of the child’s mother.
Two milliliters of whole blood samples were submitted to a rapid
and cost-effective DNA extraction according to the protocol described
elsewhere7. Briefly, 200 µL of EDTA- whole blood were added to a
1.5 mL microtube containing 800 µL of a 170 mM NH4Cl solution.
After centrifugation, the supernatant was discarded and the cell pellet
was re-suspended in 300 µL of a 10 mM NaCl/EDTA solution. After
a second centrifugation, the supernatant was discarded and the cell
pellet was re-suspended in 500 µL of a 50 mM NaOH solution.
Samples were incubated at 100 0C for five minutes and then re-
centrifuged. The DNA was contained within the supernatant liquid
and its concentration estimated at 260 nm by UV spectrophotometry
(Beckman, DU-70).
DNA EXTRACTION FROM SERUM SAMPLES: Serum and
plasma samples are known to contain inhibitors of PCR which must be
removed by DNA extraction techniques11,12,16. This is the reason why,
in the present study, DNA was extracted from 200 µL of serum using
spin columms (QIAamp DNA Blood Mini kit, Qiagen, Valencia, CA),
eluted in 50 µL of AE buffer (Qiagen) previously treated with proteinase
K (20 µg/µL). Afterwards, serum DNA samples were stored at -20 °C
until needed. It is not possible to determine DNA concentration by UV
spectrophotometry when DNA is obtained by means of this extraction
kit so that we fixed the volume of serum samples at the beginning
(200 µL ) and the volume of DNA sample to be used in amplifications
(20 µL).
POLYMERASE CHAIN REACTION: PCR assays were
performed in 50 µL of total volume containing either 20 µL of genomic
DNA from whole blood samples (approximately 1 µg of genomic DNA),
or 20 µL of DNA from serum samples (DNA concentration not
determined), 100 mM of Tris-HCl and 500 mM of KCl; 2.5 units of
Taq DNA polymerase (Amersham Biotech, USA), 200 µM of dNTP
(Invitrogen, USA), 1.5 mM of MgCl2; 0.4 µM of each EBV gp 220
primer: gp1 sense – 5’- GGC TGG TGT CAG CTG TGT TA - 3’ and
gp2-anti-sense 5’ - CCT TAG GAG GAA CAA GTC CC -3’ (synthesized
by MWG Biotech). Samples were overlaid with 50 µL of sterile mineral
oil. An initial denaturation step of five minutes at 95 °C was followed
by 40 cycles of 30 seconds at 95 °C, 30 seconds at 57 °C and one
minute at 72 °C. A final extension time of five minutes at 72 °C ended
the amplification (M.J. Research PT-150 minicycler). PCR products
(239 bp) were detected in 2% ethidium bromide-stained agarose (Sigma,
USA) gels21 in a horizontal electrophoresis apparatus (Horizon H58,
Life Technologies, USA). DNA-PCR was performed to amplify a
portion of the gene coding for the EBV gp220 with a detection limit of
100 viral copies. In each experiment, a negative control composed of
either sterile water instead of genomic or serum human DNA, or DNA
from a non infected individual was tested, as well as a positive control
(EBV DNA from viral cultures).
RESULTS
In the present study we aimed at analyzing the association between
EBV-DNA detection in serum samples and the occurrence of EBV
reactivations in an immunosuppressed heart transplant child by means
of a standard non quantitative PCR protocol which is able to detect
100 viral copies of a specific fragment from the EBV gp220 gene.
Some of the PCR results are shown in Figure 1.
Fig. 1 - EBV-DNA amplification from whole blood and serum samples of the 8-year-old
heart transplant patient. Lane 1: molecular weight marker 100 bp ladder (Invitrogen); lane 2:
negative control (sterile water instead of DNA); lane 3: positive sample corresponding to
DNA from whole blood (25th month); lane 4 positive sample corresponding to DNA from
serum sample (25th month); lane 5: negative control corresponding to DNA from whole
blood sample of a non-infected individual; lane 6: positive sample corresponding to DNA
from whole blood (12th month); lane 7: negative sample corresponding to DNA from serum
(12th month); lane 8: positive control corresponding to DNA from EBV virus (amplicon of
239 bp).
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Initially, during the first episode of acute infectious mononucleosis
at the age of five, the child presented with positive VCA-IgM and IgG,
and negative EBNA-IgG (acute EBV infection profile). Fourteen months
later, VCA-IgM became undetectable while VCA-IgG remained
positive. At that time, EBNA-IgG began to be synthesized. This
serologic pattern (positive VCA-IgG and EBNA-IgG and negative VCA-
IgM) has been maintained since then until the 36th month of follow-
up, even during clinical episodes suggestive of EBV reactivations (post-
acute EBV infection or carrier state serological profile), thus restricting
the use of serological parameters to control EBV reactivations.
All twenty-four whole blood DNA samples extracted from
peripheral blood leukocytes were EBV-DNA positive. On the contrary,
only twelve out of twenty-four serum samples were EBV-DNA positive.
Some of the PCR results are shown in Figure 1. PCR-positive serum
samples corresponded, in the majority of cases, to the ones obtained
during hospitalization and life threatening episodes, just before
acyclovir treatment was initiated. The 25th serum sample corresponded
to a prolonged and critical hospital staying. At that time, along with
the peripheral blood leukocyte and the serum sample, EBV-DNA was
also detected in the eye (aqueous humor). Conversely, the other twelve
EBV-DNA negative serum samples were drawn either during
ambulatory follow-up, or at the end of antibiotics and antiviral therapy,
and in most of the episodes the patient was doing well. Clinical features,
laboratory data as well as therapeutic measures adopted during the 36
months of follow-up were summarized in Table 1.
Statistical analysis enabled us to measure the agreement of the
two parameters, i.e., positive EBV-DNA-PCR in serum samples and
the need of hospitalization and antiviral treatment. For that, we applied
the Kappa test (SPSS 12.0 for windows) which has shown a value of
0.750 (p < 0.001).
Table 1
Description of clinical and laboratory data (serum PCR results) of the 8-year-old heart transplant patient during the 36 months follow-up. The moment of blood
sampling was registered from the 1st up to the 36th month as well as the need of hospitalization recorded as yes = Y or no = N. Serum PCR results were recorded as
positive or negative (+ or -)
Month of Need of Serum PCR Clinical status
follow-up hospitalization
1 Y + Acute infectious mononucleosis (lymphadenopathy, fever). Cyclosporine A + antibiotics +
acyclovir
2; 3 N - Stable. Ambulatory treatment. Cyclosporine A
4 Y + Lymphadenopathy, fever, pneumonia. Antibiotics + acyclovir. Cyclosporine A
5; 8 N - Stable. Ambulatory treatment. Cyclosporine A
9; 10 Y + Pharyngitis, lymphadenopathy, fever, myocarditis. Antibiotics + acyclovir. Cyclosporine A
11; 12; 14 N - Stable. Ambulatory treatment. Cyclosporine A
17 Y + Pharyngitis, lymphadenopathy, fever, myocarditis. Antibiotics + acyclovir. Cyclosporine A
18 N - Stable. Ambulatory treatment. Cyclosporine A
20 Y + Lymphadenopathy, fever, pneumonia, myocarditis. Antibiotics + acyclovir. Cyclosporine A
21; 24 N - Stable. Ambulatory treatment. Cyclosporine A
25;26;27;28;29 Y + Cyclosporine substituted for tacrolimus. Lymphadenopathy, pneumonia, hepatomegaly,
jaundice, myocarditis, cardiac insufficiency, uveitis (EBV-DNA PCR positive in aqueous
humor). Broad spectrum antibiotics.
30;34;36 N - Stable (day-care treatment). Asymptomatic. Tacrolimus
DISCUSSION
The present study has found positive amplifications in all 24 DNA
samples extracted from whole blood samples. These results were
expected because the patient is chronically infected and has followed
immunosuppression with cyclosporine A and latter with tacrolimus.
In this group of patients, effective clearance of EBV is not the rule8.
A number of studies have used serum samples to evaluate the
association of EBV activity with the onset of lymphoproliferative diseases
in immunosuppressed patients5,20. Other studies have pointed out the
correlation between positive EBV-DNA in serum samples and the activity
of disease before and after the advent of Real-Time PCR and other
quantitative techniques1,2,17,22. However, some authors have reported that
serum is an undesirable clinical specimen for EBV DNA load monitoring
because it omits the presence of cell-associated virus, and uncontrolled
cell lysis may give irreproducible results or overestimation of the DNA
load19. Even so, we detected EBV-DNA in all 24 whole blood samples
and in only 12 out of 24 serum samples in the present study. Positive
PCR tests were found among samples from episodes in which the patient
was hospitalized whereas negative PCR results corresponded mostly to
the occasions in which the child was clinically stable.
According to the analysis performed by means of the Kappa test
there is a significant statistical agreement between EBV disease activity
(in the present study represented by the need of hospitalization and
antiviral treatment) and the finding of EBV-DNA in serum samples by
PCR (value 0.75; p < 0.001).
The data presented herewith, although based on the study of 24
clinical episodes of a single immunosuppressed and EBV chronically
infected patient, suggest that a rapid and cost-effective EBV-DNA
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detection in serum samples (cell-free EBV virus) by PCR with a
detection limit of 100 viral copies per µg of human DNA might be
used as a marker of disease activity in chronically infected
immunocompromised patients when a Real-Time PCR or another
reliable quantitative amplification technique is not available.
In conclusion, there was a statistically significant association
between EBV-DNA detection in serum samples and the occurrence of
overt disease as stated by clinical signs and symptoms, the need of
hospitalization and antiviral therapy.
RESUMO
Detecção de EBV-DNA em amostras de soro de criança
imunodeprimida durante três anos de seguimento: associação de
dados clínicos e de PCR com a infecção ativa
Vinte e quatro amostras de sangue total e de soro foram colhidas
durante seguimento por 36 meses de criança de oito anos de idade,
imunodeprimida devido a transplante cardíaco. O paciente apresentou
VCA-IgG e IgM positivos e EBNA-IgG negativo aos cinco anos de
idade quando foi diagnosticada mononucleose infecciosa. Quatorze
meses depois o VCA-IgG e o EBNA-IgG eram positivos e o VCA-IgM
negativo. Este padrão sorológico persiste desde aquela época mesmo
durante episódios sugestivos de reativação. As amostras de sangue total
e de soro foram analisadas pela Reação em Cadeia da Polimerase (PCR)
que amplificou fragmento oriundo da gp220 do EBV (detecção de 100
cópias virais). Todas as 24 amostras de sangue total e 12 amostras de
soro foram positivas por PCR. Com o objetivo de verificar se a detecção
de DNA do EBV em soro estaria associada à reativação da doença, os
resultados de PCR foram analisados em relação à necessidade de
hospitalização e uso de anti-viral. O teste de Kappa mostrou que existe
concordância entre a presença de DNA do EBV em soro e a necessidade
de hospitalização e tratamento com anti-virais (valor de 0,750; p <
0,001). Concluímos que a detecção de DNA do EBV em amostras de
soro de pacientes imunosuprimidos poderia ser usada como marcador
laboratorial de atividade da infecção quando técnicas quantitativas de
amplificação não estiverem disponíveis.
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